GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » YoY Rev. per Sh. Growth
中文

Affymax (Affymax) YoY Rev. per Sh. Growth

: -92.86% (As of Jun. 2014)
View and export this data going back to 2006. Start your Free Trial

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Affymax's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2014 was -92.86%.

Affymax's Revenue per Share for the three months ended in Jun. 2014 was $0.00.

Affymax YoY Rev. per Sh. Growth Historical Data

The historical data trend for Affymax's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 -24.56 -68.79 81.10 -98.58

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.58 -100.00 -100.00 -100.00 -92.86

Affymax YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Affymax's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2013 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2013 )
=(Revenue per Share (A: Dec. 2013 )-Revenue per Share (A: Dec. 2012 ))/ | Revenue per Share (A: Dec. 2012 ) |
=(0.037-2.597)/ | 2.597 |
=-98.58 %

Affymax's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2014 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2014 )
=(Revenue per Share (Q: Jun. 2014 )-Revenue per Share (Q: Jun. 2013 )) / | Revenue per Share (Q: Jun. 2013 )) |
=(0.001-0.014)/ | 0.014 |
=-92.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affymax YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Affymax's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
TSXV:APC APOP BOM:532871 ONTX BTHE TSXV:PBS GLPH BRTX AURX PTEO AKAOQ TIKRF NVIV ATMS CAPS HSTC TSXV:COT BOM:542765 TSXV:MFS RSPI
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Website
http://www.affymax.com
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009